News

Liquidia’s LIQ-001is a seasonal influenza vaccine for protection in the elderly and represents the company’s migration from proof of concept to the clinical application of PRINT technology. Liquidia

Dynavax’s Heplisav is a TLR9 agonist and Engerix-B is a commercially available hepatitis B vaccine. Dynavax’s Phase 3 Heplisav Short-regimen Trial (PHAST), a previously reported Phase 3 multicenter

VTX-2337 was proven to be safe and well tolerated with a predictable pharmacokinetic profile in 33 patients. In addition, VTX-2337 showed dose-dependent pharmacologic activity, according to the study

The Ampicillin and Sulbactam product will be sold in 1.5g and 3g single-dose and 15g pharmacy bulk package vials. However, Ampicillin product will be sold in five presentations:

Following FDA’s complete response letter, HGS and Novartis have jointly decided to terminate the development of Zalbin. Zalbin is a genetic fusion of human albumin and interferon alfa

The studies were conducted to evaluate the efficacy and safety of two dosage strengths of RHUCIN, an investigational drug, for the treatment of acute attacks in patients with

Tapentadol is a centrally-acting analgesic with a dual mode of action as an agonist at the µ-opioid receptor and as a norepinephrine reuptake inhibitor. J&JPRD’s NDA was filed

Mayo Clinic Research Informatics associate dean Gloria Petersen said that Mayo’s Clinical Trials Management System (CTMS) will eliminate the duplication, delays and errors caused by manual data entry

The patents cover the various properties of Protectan CBLB612 and related compounds, including composition of matter and methods of use for protecting against apoptosis. Protectan CBLB612 is a